Pharmaceutical companies and other stakeholders are invited to comment on a revised procedure for CADTH’s drug reimbursement review processes (that is, the pan-Canadian Oncology Drug Review, the Common Drug Review, the Interim Plasma Protein Product Review, and the Interim Process for Cell and Gene Therapies).
To help pharmaceutical compa...
Because of the prevalence and burden of chronic pain, health care providers are in search of the best multifaceted approach for treatment knowing that relying on opioids alone can be ineffective and carries substantial risks. Join CADTH for a webinar on the current evidence on physical activity for chronic, non-cancer pain. The target audience f...
